e21696 Background: Cancer-related anemia is an important factor that affects the clinical efficacy and quality of life for patients with advanced gastric cancer. This study is to observe the clinical efficacy of Yizhongshengxue Capsule, which is an herbal formula, on advanced gastric cancer-related anemia. Methods: A total of 96 eligible patients were randomized into three arms: 46 patients in the experimental arm, 26 patients in the positive control arm, and 24 patients in the negative control arm. All three arms received basic treatment of conventional medicine. Meanwhile, the experimental arm received Yizhongshengxue Capsule at the dosage of 3 capsules, 3 times daily. The positive control arm received Fufangejiao Syrup at the dosage of 20 ml, 3 times daily. The negative control arm received only basic treatment of western medicine. The course of treatment was 5 weeks. Results: After the 5-week-treatment, there was a statistically significant rise ( p<0.05) of hemoglobin(HGB) in both experimental arm and positive control arm. The negative control arm had no statistically difference of HGB ( p>0.05) before and after the treatment. Symptoms of dizziness, fatigue, loss of appetite, palpitation and insomnia in experimental arm were improved after the treatment ( p<0.05). Symptoms of fatigue and loss of appetite in positive control arm were alleviated after the treatment ( p<0.05). The negative control arm had no statistically difference in the above symptoms ( p>0.05) before and after the treatment. Furthermore, there was a significant improvement of dizziness, loss of appetite, palpitation and insomnia in the experimental arm compared to the negative control arm ( p<0.05). Finally, an improvement of the Karnofsky Performance Score(KPS) was seen only in the experimental arm after the treatment compared to that before the treatment ( p<0.05). Conclusions: Our study shows that Yizhongshengxue Capsule can not only improve the clinical symptoms and quality of life in patients with advanced gastric cancer-related anemia, but also reduce or even reverse the trend of HGB decrease. Therefore, it is very promising in treating cancer-related anemia. Clinical trial information: ChiCTR-TRC-13003604.